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Abstract
Aims: Accurate liver fibrosis staging is crucial for the management of chronic hepatitis C (CHC). The invasiveness and cost
burden of liver biopsy have driven the search for new noninvasive biomarkers of fibrosis. Based on the link between serum
angiopoietin-1 and 2 levels and CHC progression, we aimed to determine the value of these angiogenic factors as
noninvasive biomarkers of liver fibrosis.
Methods: Serum levels of angiopoietin-1 and -2 were measured by ELISA in 108 CHC patients who underwent pretreatment
liver biopsy. The correlation between angiopoietins and clinical and demographic variables with liver fibrosis was analyzed
by univariate regression. Significant factors were then subjected to multivariate analysis, from which we constructed a novel
noninvasive liver fibrosis index (AngioScore), whose performance was validated in an independent series of 71 CHC patients.
The accuracy of this model was compared with other documented fibrosis algorithms by De Long test.
Results: Angiopoietins correlated significantly with hepatic fibrosis; however, only angiopoietin-2 was retained in the final
model, which also included age, platelets, AST, INR, and GGT. The model was validated and behaved considerably better
than other fibrosis indices in discriminating all, significant, moderate and severe liver fibrosis (0.886, 0.920, 0.923). Using
clinically relevant cutoffs, we classified CHC patients by discarding significant fibrosis and diagnosing moderate and severe
fibrosis with greater accuracy, sensitivity, and specificity.
Conclusions: Our novel noninvasive liver fibrosis model, based on serum angiopoietin-2 levels, outperforms other indices
and should help substantially in managing CHC and monitoring long-term follow-up prognosis.
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Introduction
Hepatitis C virus (HCV) infection is a major global health
problem, because it effects chronic injury of the liver in a high
percentage of acutely infected patients [1]. The persistence of
inflammatory responses and cellular damage promote disease
progression toward fibrosis, cirrhosis, and hepatocellular carcino-
ma [2,3]. Thus, accurate evaluation of hepatic fibrosis has become
the primary goal in managing the progression of chronic hepatitis
C (CHC), because its morbidity and mortality are linked to
cirrhosis and its complications.
In addition, the decision of physicians to administer antiviral
therapy depends on the stage of fibrosis [4]. Liver biopsy (LB) is
the standard for determining the stage of fibrosis, but due to its
invasiveness, risk of complications, and potential for sampling
errors, noninvasive markers are being sought as alternative
diagnostic tools [5,6,7,8,9,10].
Liver fibrosis results from an inappropriate wound-healing
response to chronic damage that elicits excess deposition of matrix
compounds and scarring, which ultimately alters liver structure
and function [3]. Simultaneously, angiogenesis is stimulated to
provide oxygen and nutrients to injured tissue; unfortunately,
chronic damage dysregulates the repair processes, leading to
capillarization of hepatic sinusoids, which restricts the blood
supply, exacerbating tissue injury, fibrogenesis, and angiogenesis
[11,12,13,14]. This sequence of events appears to govern the
progression of CHC to cirrhosis and hepatocellular carcinoma
(HCC) [15,16].
One of the most significant signaling pathways in pathological
angiogenesis and HCC is the angiopoietin/Tie2 system
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[17,18,19]. Angiopoietin-1 and -2 (Ang1 and Ang2, respectively)
are the most potent regulators of neovascularization, vascular
remodelling, and maturation, through agonistic and antagonistic
autophosphorylation, respectively, of their common tyrosine
kinase receptor, Tie2 [20]. The balance between the signals that
are generated by Ang1 and Ang2 has pathological effects–the
Ang1/Ang2 equilibrium is altered in cancers, such as HCC, a
highly vascularized tumor [21,22,23], and in diverse chronic liver
diseases, such as primary biliary cirrhosis (PBC) and viral hepatitis
B and C [24,25,26,27], implicating angiopoietins as biomarkers of
liver disease progression and putative therapeutic targets [28,29].
We noted a link between serum Ang2 levels and the failure of
response of CHC patients to antiviral treatment [25]; further,
Ang2 and CHC progression have been associated directly in an
earlier study [29]. Thus, we aimed to determine the value of
angiopoietins in monitoring the evolution of CHC and preventing
disease progression. This analysis resulted in the development of a
novel noninvasive model of liver fibrosis (AngioScore), which was
validated in an independent cohort of CHC patients, outperform-
ing other documented procedures.
Materials and Methods
Patients
The training group included 108 CHC serum samples from the
collection of the Liver Unit, Hospital Universitario La Princesa,
randomly selected from patients without HIV, hepatitis B virus
coinfection, or evidence of autoimmune liver disease who
underwent pretreatment liver biopsy and gave written informed
consent for their experimental use.
Similarly, the validation set comprised serum samples that were
available in the same collection (total of 71) from CHC patients
without coinfections or liver autoimmunity who underwent
pretreatment liver biopsy and authorized their use for investiga-
tional purposes by signed informed consent.
The study protocol was approved on February 15, 2010 by the
ethics committee of Hospital Universitario de La Princesa and was
conducted per the Declaration of Helsinki.
Viral load in the serum of all patients was measured by COBAS
AMPLICOR assay (Roche Molecular Systems, Branchburg, NJ),
and HCV genotyping was performed by reverse-hybridization line
probe assay (INNO-LiPAHCV; Innogenetics, Zwijndreht, Bel-
gium). Serum samples were also subjected to routine laboratory
tests at the biochemical laboratory of Hospital de La Princesa
using common commercial methods. Total bilirubin, ALP, ALT,
AST, GGT, albumin, serum cholesterol, prothrombin activity,
INR, and platelets were measured.
Liver Histology
Liver biopsies from patients were obtained by percutaneous
needle extraction (HepafixH, B. Braun Melsungen AG, Melsun-
gen, Germany) under echographic control and were paraffin-
embedded for routine anatomopathological examination. Histo-
logical features were analyzed in liver biopsies (median length
1.90 mm, 95% CI 1.78–2.02) per the METAVIR classification
system [30], which scores the stage from F0 to F4: F0 is the
absence of fibrosis, F1 is portal fibrosis without septa, F2 is portal
fibrosis with rare septa, F3 is numerous septa without cirrhosis,
and F4 is cirrhosis.
Table 1. Baseline characteristics of patients with chronic hepatitis C.
PATIENTS T (n = 108) V (n = 71) p ALL (n = 179)
Sex (M/F) 71/37 44/27 0.608 115/64
Age (years) 46 (25–65) 44(22–67) 0.275 45 (22–67)
Viral load (6105 IU/mL) 7.4 (3.0–13.0) 5.4 (2.2–12.0) 0.528 6.7 (2.2–13.0)
HCV genotype, n (%) 0.267
1 84 (77.7) 60 (85.5) – 144 (80.4)
Non-1 24 (22.3) 11 (15.5) – 35 (19.6)
Stage of liver fibrosis, n (%) 0.004
F1 25 (23.3) 17 (23.9) – 42 (23.5)
F2 31 (28.7) 35 (49.6) – 66 (36.9)
F3 33 (30.5) 7 (9.6) – 40 (22.3)
F4 19 (17.5) 12 (16.9) – 31 (17.3)
AST (UI/L) 56.0 (39.0–91.8) 46.0 (34.0–69.0) 0.037 53.0 (36.0–84.0)
ALT (UI/L) 88.5 (64.3–128.8) 69.0 (46.0–106.0) 0.006 81.0 (58.0–121.0)
ALP (UI/L) 123.5 (79.3–190.3) 135.0 (73.0–178.0) 0.667 126.0 (77.0–181.0)
GGT (UI/L) 48.5 (26.0–91.0) 36.0 (20.0–72.0) 0.066 45.0 (25.0–82.0)
Prothrombin Activity (%) 93.6 (85.5–101.0) 90.1(81.0–102.3) 0.428 92.8 (83.7–101.1)
INR 1.0 (0.9–1.1) 1.0 (0.9–1.1) 0.602 1.0 (0.9–1.1)
Bilirrubin (mg/dL) 0.7 (0.5–0.9) 0.7 (0.5–0.9) 0.965 0.7 (0.5–0.9)
Platelet count (6109/L)a 190.0 (151.0–224.0) 197.0 (160.0–237.0) 0.586 193.5 (152.0–232.5)
Cholesterol Total (mg/dL)b 171.5 (153.7–189.0) 165.0 (151.3–191.0) 0.367 169.0 (152.8–189.0)
Albumin (g/dL)c 4.3 (4.1–4.5) 4.4 (4.2–4.5) 0.374 4.3 (4.1–4.5)
Data are shown as number of patients (percentage) or median value (25th–75th percentile), except for age (median and range). a n = 178; b n = 174 and c n = 170. T,
Training Group; V, Validation Group. Significant variables are shown in bold.
doi:10.1371/journal.pone.0066143.t001
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Ang1 and Ang2 Concentrations in the Serum of CHC
Patients
Circulating Ang1 and Ang2 levels were measured in the serum
samples from CHC patients on the same day that they underwent
liver biopsy–ie, before initiation of antiviral combination therapy–
using the respective human ELISA kits following the manufactur-
er’s recommendations (Quantikine: R&D Systems, Minneapolis,
MN). All measurements were made in duplicate, and the
absorbance was read at 450 nm and corrected at 570 nm.
Serological Indices of Fibrosis
Other liver fibrosis scores were calculated as follows:
1) APRI [31]: 1006(AST (IU/L)/40)/platelet count (109/L)
2) FIB4 [32]: age (years)6AST (IU/L)/platelet count (109/
L)6ALT (IU/L)K
3) King [33]: age (years)6AST (IU/L)6INR/platelet count
(109/L)
4) AAR score [34]: AST (IU/L)/ALT (IU/L)
5) GUCI [35]: (AST6INR6100)/platelet count (109/L)
6) LOK [36]: 25.56–(0.00896platelet count (109/
L))+(1.266AST (IU/L)/ALT (IU/L)) +5.276INR
7) FORNS [37]: 7.811– (3.1316Ln platelet count (109/
L))+(0.7816Ln GGT (IU/L))+(3.4676Ln age (years)) –
0.0146cholesterol
8) FI [38]: 8.0 2 0.016platelet count (109/L) 2 serum albumin
(g/dL)
9) FCI [39]: (ALP6bilirubin)/(albumin6platelet count)
Statistical Analysis
Comparisons of Ang1 and Ang2 serum levels between fibrosis
stages were analyzed by Mann-Whitney U-test using a two-sided
p-value; p,0.05 was considered significant. The relationship
between angiopoietins and clinical and demographic variables
with liver fibrosis was analyzed by univariate logistic regression. All
variables that were significantly associated with fibrosis (p,0.05)
were analyzed by step-backward multiple regression, in which
none of the variables was forced to be included in the model. The
covariates that were retained in the final model were used to build
a novel liver fibrosis index (AngioScore), which was then validated
with the validation set (n = 71).
The diagnostic performance of angiopoietins, the established
fibrosis indices, and our novel fibrosis model was analyzed using
area under the receiver operating characteristic curves (AUC-
ROCs) to discriminate significant fibrosis (F.1), moderate fibrosis
(F.2), and severe fibrosis (F.3). Sensitivity (Se), specificity (Sp),
positive predictive value (PPV), negative predictive value (NPV),
positive and negative likelihood ratio (LR), and accuracy (ACC)
were calculated per standard methods and expressed as percent-
ages. Optimal cutoff values were chosen to maximize the sum of
sensitivity and specificity (Youden index) and were corrected
according to the global prevalence of each fibrosis stage [40]
(MedCalc version 12.3.0.0, Mariakerke, Belgium) to minimize the
effects of selection bias. In addition, the clinical relevance of cutoffs
that corresponded to sensitivities and specificities above 90% were
examined.
The performance of AngioScore was compared with other
fibrosis indices using the entire cohort of patients by De Long test
(MedCalc 12.3.0.0, Mariakerke, Belgium).
Figure 1. Serum levels of Ang1 and Ang2 in the training set of
108 CHC patients. Distribution of Angiopoietin-1 (A), Angiopoietin-2
(B), and Ang2/Ang1 (C) serum concentrations against METAVIR fibrosis
stage. Medians are represented by horizontal lines. Two-sided p-values
were calculated by non-parametric Mann-Whitney U Test.
doi:10.1371/journal.pone.0066143.g001
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Results
Demographics and Clinical Characteristics of CHC
Patients
The main demographic, laboratory, and histological features of
the training series of CHC patients (n = 108) were similar to those
of the validation set (n = 71), except for AST and ALT, which were
significantly higher in the training group (p,0.05 for both), and
fibrosis stage–the training group included more patients with
advanced fibrosis (p,0.005)–as shown in Table 1.
Ang1 and Ang2 Serum Levels in the Training Cohort
Serum levels of Ang1 decreased gradually as the fibrosis
progressed to more advanced stages–more so for F4 compared
with lower stages (p,0.05, Figure 1a). In contrast, Ang2 serum
concentrations rose progressively with the stage of fibrosis–a
pattern that was significant between F1 and all other fibrosis stages
and between F2 and F4 (Figure 1b). Notably, the Ang2/Ang1 ratio
increased with the stage of fibrosis and differentiated F2 and F3, as
well as F3 and F4 (p,0.05), the most clinically relevant endpoints
(Figure 1c).
By AUC-ROC analysis (Figure 2), Ang2 characterized patients
with significant fibrosis stage (F.1), as did Ang1 in classifying
cirrhotic individuals (AUC of 0.747 and 0.779, respectively), as
suggested by Mann-Whitney U-test. Based on this contrast, we
analyzed the predictive accuracy of the Ang2/Ang1 ratio and
noted that it performed better than Ang1 and Ang2 alone,
achieving an AUC of 0.804 for F.3.
Liver Fibrosis-related Variables
The relationship between Ang1, Ang2, and demographic and
clinical variables with liver fibrosis was first evaluated in the
training set of CHC patients (n = 108). Serum Ang1 levels were
inversely related to fibrosis (p = 0.01); in contrast, Ang2 was
associated directly with fibrosis, as demonstrated by univariate
regression analysis (p = 5.4961026). The Ang2/Ang1 ratio was
linked to fibrosis, like AST, age, ALT, GGT, platelet count, INR,
albumin, and bilirubin (Table 2).
All variables that were significantly related to liver fibrosis
(Ang1, Ang2, Ang2/Ang1, age, AST, ALT, GGT, platelet count,
INR, albumin, and bilirubin) were analyzed together by step-
backward multiple regression, wherein Ang2, age, platelet count,
INR, AST, and GGT were associated independently with liver
fibrosis (Table 2). However, Ang1, ALT, albumin, and bilirubin
were not effective when analyzed in combination with the other
covariates and were automatically removed from the multivariate
model.
Validation and Performance of a New Index for
Noninvasive Assessment of Liver Fibrosis
The novel liver fibrosis model was applied to the training group
of CHC patients (n = 107, because platelet count was unavailable
in 1 patient) and was accurate in discerning all, F.1, F.2, and
F.3 fibrosis (AUC .0.9). The model continued to perform well
when tested with the validation set (n = 71), discriminating F.2
(AUC .0.8) and F.3 (AUC .0.9), the chief clinical endpoints
(Table S1).
Figure 2. Performance of serum angiopoietin level in the
training set of CHC patients. The area under the receiver operating
characteristic curves (AUC-ROCs) of Ang1, Ang2, and Ang2/Ang1 for
significant fibrosis (A), moderate fibrosis (B), and severe fibrosis-cirrhosis
(C), respectively, are shown in brackets (n = 108).
doi:10.1371/journal.pone.0066143.g002
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Next, the fibrosis-related variables were included in AngioScore,
a new noninvasive model of CHC liver fibrosis that was calculated
using the total population (n= 178), after considering their
distribution functions, as follows:
AS~{6:634z 1:083|LogAng 2ð Þz
1:792|LogAGEð Þz 3:782|LogINRð Þ
z 1:052|LogASTð Þ{ 0:005|plateletsð Þ
z 0:653|LogGGTð Þ
This model was then compared with other fibrosis indices
(APRI, FIB4, King, AAR, GUCI, Lok, Forns, FI, and FCI) for the
178 CHC patients; their correlation with liver fibrosis stage,
reflected that our model performed best (p,0.0001, Table S2).
In addition, the diagnostic performance of all indices in the
entire cohort was evaluated by AUC-ROC analysis, which
indicated that our model was superior to the others in staging
liver fibrosis: AUC values of 0.886 for F.1, 0.920 for F.2, and
0.923 for F.3. The cutoffs that corresponded to the Youden index
for our model had a sensitivity and specificity of approximately
80% or higher and accuracy above 80% for all stages (F.1, F.2,
and F.3; Table 3).
Moreover, the precision of our index was significantly better
than most fibrosis scores in differentiating all, significant,
moderate, and severe fibrosis (De Long test, p,0.05; Table 4).
Because the distribution of fibrosis stages in our population
differed from that of a large population (33,121 CHC patients
[40], yielding 48% vs 72% for F.1, 26% vs 40% for F.2, and
12% vs 18% for F.3, respectively), the optimal cutoffs for all liver
fibrosis indices were recalculated accordingly (MedCalc version
12.3.0.0). This analysis yielded the same optimal diagnostic
parameters for our liver fibrosis model, except for 1 discrepan-
cy–the optimal cutoff for F.3 was 3.0687 instead of 2.5393,
obtained by the Youden index, demonstrating high specificity
(93.88%) and acceptable sensitivity (67.74%). Once the corrected
optimal cutoff for F.3 was applied, the accuracy of our model
reached 90.7% (Table S3).
Diagnostic Criteria
Based on the clinical relevance of accurately predicting CHC
patients without significant fibrosis (F#1) and those with moderate
or advanced fibrosis, we examined the cutoffs that corresponded to
sensitivities or specificities over 90% in addition to the optimal
cutoffs (Figure 3). A value of 1.58, corresponding to a specificity of
above 90%, identified patients with low fibrosis, correctly
classifying 67.5% of patients with an accuracy of 76.8%
(Figure 3); however, the optimal cutoffs were more effective in
identifying patients with moderate and severe fibrosis (51.4% and
67.7% of well-classified patients, respectively) than those related to
specificities .90%–2.40 vs 2.38 and 3.07 vs 2.90, respectively, with
sensitivities of 81.43% and 74.19% and comparable accuracies
(88.3% and 88.5%).
An in-depth examination of all diagnostic criteria for all liver
fibrosis indices (Youden, optimal, above 90% sensitivity, and over
90% specificity) demonstrated the superior accuracy of our model
in distinguishing all, significant, moderate, and severe liver fibrosis
(Table S3). Only the optimal cutoffs for GUCI and FCI had
greater accuracy for F.3 than that of the novel index (91.06 and
91.72 vs. 90.74, respectively) but had worse sensitivity (35.48 and
31.03 vs. 67.74, respectively).
Discussion
Chronic liver damage (CLD) often leads to advanced fibrosis
and cirrhosis, due to the persistent and altered stimulation of
immune responses and tissue repair mechanisms. Excess deposi-
tion of extracellular matrix (ECM) components distorts the hepatic
architecture by forming ECM complexes and fibrous scars.
Fibrosis is a fundamental complication of CLD, which often
progresses to cirrhosis and HCC after 15 to 20 years in a
significant proportion of HCV-infected patients [2,41].
Table 2. Association of angiopoietins and clinical and demographic variables with liver fibrosis in the training set of CHC patients.
Parameter
Standardized b
Coefficienta
Nonstandardized
Coefficient (95% CI)a p valuea
Standardized b
Coefficientb
Nonstandardized
coefficient (95%CI)b p valueb
Ang1 20.310 3.352 (2.711–3.994) 0.001 0.020 1.2061026 (28.1761026–
1.0561025)
0.800
Ang2 0.422 2.161024
(1.261024–3.061024)
5.4961026 0.167 8.1461025 (1.1861025–
1.5161024)
0.022
Ang2/Ang1 0.417 0.062 (0.036–0.088) 7.2461026 – – –
Age 0.344 0.038 (0.018–0.057) 2.7061024 0.190 0.021 (0.006–0.036) 0.006
AST 0.435 0.009 (0.005–0.013) 2.6061026 0.240 0.006 (0.002–0.009) 0.004
ALT 0.321 0.004 (0.002–0.006) 0.001 20.095 20.001 (20.005–0.003) 0.504
GGT 0.351 0.004 (0.002–0.006) 1.9061024 0.184 0.002 (3.0261024–0.004) 0.021
ALP 0.130 0.002 (20.001–0.004) 0.180 – – –
Platelet countc 20.518 20.010 [20.013–(20.007)] 1.0861028 20.271 20.005 [20.008–(20.002)] 0.000
INR 0.452 4.916 (3.048–6.783) 9.0661027 0.323 3.369 (1.855–4.882) 0.000
Albumind 20.205 20.594 [21.160–(20.029)] 0.039 0.062 0.181 (20.246–0.608) 0.402
Total
Cholesterole
20.109 20.003 (20.009–0.003) 0.268 – – –
Total Bilirubin 0.205 0.651 (0.051–1.250) 0.034 0.021 0.065 (20.384–0.513) 0.775
aUnivariate regression p value; bMultivariate regression p value; n = 108, except for cn = 107, dn = 101, en = 106. Significant variables are shown in bold.
doi:10.1371/journal.pone.0066143.t002
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Table 3. Accuracy of AngioScore and other liver fibrosis indices in the total cohort of CHC patients.
F.1
AUC-ROC
(95%CI) Cutoffa Se 95%CI Sp 95%CI +LR 95%CI 2LR 95%CI +PV 95%CI 2PV 95%CI ACC
AS 0.886
(0.829–0.928)
.1.9248 79.41 71.6–85.9 83.33 68.6–93.0 4.76 2.4–9.4 0.25 0.200–
0.400
81.5 71.4–89.2 81.4 72.1–88.7 81.5
APRI 0.822
(0.758–0.875)
.0.7158 58.09 49.3–66.5 90.48 77.4–97.3 6.10 2.4–15.7 0.46 0.400–
0.600
84.9 73.1–93.0 70.0 61.0–78.1 74.9
FIB4 0.855
(0.795–0.903)
.1.2030 72.06 63.7–79.4 83.33 68.6–93.0 4.32 2.2–8.6 0.34 0.200–
0.500
80.0 69.2–88.3 76.4 66.9–84.3 77.9
KING 0.855
(0.795–0.903)
.10.6470 72.06 63.7–79.4 85.71 71.5–94.6 5.04 2.4–10.7 0.33 0.200–
0.400
82.3 71.7–90.2 76.9 67.5–84.6 79.2
AAR 0.554
(0.447–0.628)
.0.6486 54.01 45.3–62.6 61.90 45.6–76.4 1.42 0.9–2.1 0.74 0.600–
1.000
56.7 45.2–67.7 59.3 48.9–69.2 58.1
GUCI 0.816
(0.751–0.870)
.30.4200 57.35 48.6–65.8 92.86 80.5–98.5 8.03 2.7–24.1 0.46 0.400–
0.600
88.1 76.5–95.3 70.2 61.3–78.2 75.8
LOK 0.683
(0.609–0.750)
.–1.5009 82.35 74.9–88.4 42.86 27.7–59.0 1.44 1.1–1.9 0.41 0.200–
0.700
57.1 47.9–66.0 72.5 58.6–83.7 61.8
FORNSb 0.860
(0.799–0.908)
.4.5887 78.03 70.0–84.8 82.93 67.9–92.8 4.57 2.3–9.0 0.26 0.200––
0.400
80.8 70.5–88.8 80.4 70.8–87.9 80.6
FIc 0.675
(0.598–0.745)
.1.8300 48.46 39.6–57.4 89.74 75.8–97.1 4.73 1.8–12.2 0.57 0.500–
0.700
81.3 67.5–91.1 65.4 56.1–73.8 69.9
FCId 0.522
(0.443–0.599)
.0.1943 20.00 13.5–27.9 94.74 82.3–99.4 3.80 0.9–15.3 0.84 0.800–
0.900
77.8 53.9–93.0 56.2 47.8–64.4 58.9
F.2
AUC-ROC
(95%CI)
Cutoffa Se 95%CI Sp 95%CI +LR 95%CI 2LR 95%CI +PV 95%CI 2PV 95%CI ACC
AS 0.920
(0.870–0.955)
.2.3967 81.43 70.3–89.7 91.67 84.8–96.1 9.77 5.2–18.4 0.2 0.100–
0.300
77.4 63.1–88.2 93.4 87.6–97.0 89.0
APRI 0.882
(0.825–0.925)
.0.8069 80.00 68.7–88.6 86.11 78.1–92.0 5.76 3.5–9.3 0.23 0.100–
0.400
66.9 52.9–79.0 92.5 86.2–96.5 84.5
FIB4 0.880
(0.823–0.924)
.1.7538 72.86 60.9–82.8 87.04 79.2–92.7 5.62 3.4–9.4 0.31 0.200–
0.500
66.4 51.6–79.1 90.1 83.6–94.7 83.4
KING 0.896
(0.842–0.937)
.12.8571 87.14 77.0–93.9 75.93 66.7–83.6 3.62 2.6–5.1 0.17 0.090–
0.300
56.0 43.8–67.7 94.4 88.1–97.9 78.8
AAR 0.617
(0.542–0.689)
.0.7363 45.07 33.2–57.3 77.78 68.8–85.2 2.03 1.3–3.1 0.71 0.600–
0.900
41.6 27.8–56.4 80.1 72.1––86.6 69.3
GUCI 0.881
(0.825–0.925)
.32.1370 82.86 72.0–90.8 82.41 73.9–89.1 4.71 3.1–7.2 0.21 0.100–
0.400
62.3 49.0–74.4 93.2 87.0–97.0 82.5
LOK 0.771
(0.702–0.831)
.–0.7447 70.00 57.9–80.4 75.00 65.7–82.8 2.80 2.0–4.0 0.40 0.300–
0.600
49.6 36.9–62.3 87.7 80.1–93.1 73.7
FORNSb 0.857
(0.796–0.905)
.5.0262 91.18 81.8–96.7 68.57 58.8–77.3 2.90 2.2–3.9 0.13 0.060–
0.300
50.5 39.1–61.8 95.7 89.2–98.8 74.4
FIc 0.764
(0.693–0.826)
.1.8300 70.77 58.2–81.4 79.81 70.8–87.0 3.5 2.3–5.3 0.37 0.200–
0.500
55.2 41.3–68.5 88.6 81.2–93.8 77.5
FCId 0.696
(0.621–0.765)
.0.1513 47.69 35.1–60.5 84.47 76.0–90.9 3.07 1.8–5.2 0.62 0.500–
0.800
51.9 35.6–67.9 82.1 74.3–88.4 74.9
F.3
AUC–ROC
(95%CI)
Cutoffa Se 95%CI Sp 95%CI +LR 95%CI –LR 95%CI +PV 95%CI –PV 95%CI ACC
AS 0.923
(0.873–0.957)
.2.5393 96.77 83.3–99.9 78.91 71.4–85.2 4.59 3.3–6.3 0.041 0.006–
0.300
38.5 25.5–52.9 99.4 96.0–100.0 81.1
APRI 0.887
(0.831–0.930)
.0.7401 100.00 88.8–100 67.35 59.1–74.8 3.06 2.4–3.9 0 – 29.5 19.3–41.4 100.0 96.5–100.0 71.3
FIB4 0.858
(0.978–0.906)
.1.5558 93.55 78.6–99.2 70.07 62.0–77.3 3.13 2.4–4.1 0.092 0.020–
0.400
29.9 19.2–42.4 98.8 94.5–99.9 72.9
KING 0.878
(0.821–0.923)
.16.6327 90.32 74.2–98.0 73.47 65.6–80.4 3.40 2.5–4.6 0.130 0.040–
0.400
31.7 20.3–45.0 98.2 93.9–99.8 75.5
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Liver biopsy is considered the standard method of diagnosing
and staging liver disease, based on its value in assessing the stage of
fibrosis and necroinflammatory grade [42,43]. However, this
procedure is imprecise (yielding equivocal results in one-third of
cases) and has serious limitations–it is highly invasive and
expensive and can cause major complications. Further, fibrosis is
a marker rather than the actual endpoint of CLD progression;
thus, LB is not reasonable for the repetitive assessment of liver
fibrosis during the long-term follow-up of patients, necessitating
noninvasive markers that accurately screen the progression of
CLD before, during, and after treatment [6,44].
Several scores that are based on routine laboratory tests and
more direct fibrosis biomarkers have been proposed to assess CHC
progression, such as the aspartate aminotransferase-to-platelet
ratio index [34], Forns index [37], Fibrometer (BBL Fibro System)
[45], FibroSpect [46], Hepascore [47], Fibrotest (Biopredictive)
[48], and MP3 [49] score–of which Fibrotest is the most validated
and has recently been recommended in France as the first-line
method for assessing CHC fibrosis.
Measurement of liver stiffness by transient elastography–
Fibroscan (Echosens, Paris) [50]–is another noninvasive method
that is approved for evaluating liver fibrosis and is useful for
verifying cirrhosis (AUC.0.90), but it is notably less reliable in
diagnosing significant fibrosis (AUC,0.80). Moreover, Fibroscan
has several limitations, such as equipment cost, the need for
extensive operator experience, and the existence of confounding
factors, such as obesity and inflammation.
Based on these findings, the use of noninvasive methods is
increasingly being recommended for liver fibrosis staging, but
current tools are insufficient in supplanting LB; thus, they are
more likely to aid a diagnosis when combined in algorithms,
reserving LB for cases in which the accuracy of noninvasive tests is
inadequate–avoiding a significant number of biopsies from being
performed [6,7,51].
Notably, intrahepatic pathological angiogenesis is observed
frequently during CLD and is linked to fibrogenesis [14]. The
progression to cirrhosis correlates with enhanced vascular density
and the expression of angiogenic factors, such as VEGF-A, Ang1,
and Ang2, in cirrhotic rats [52,53], and studies have suggested that
liver pathologies, such as focal nodular hyperplasia, cirrhosis,
adenomas, and HCC, have a common etiology, for which Ang-1
and Ang-2 are the most informative markers for diagnosis.
Similarly, serum Ang-2 levels are elevated in patients with cirrhosis
of various etiologies, suggesting that Ang-2 is a marker that can be
used to detect the degree of liver injury [24,26,28,54].
Our study, initially performed in 108 CHC patients and
validated in an independent cohort of 71 CHC patients,
demonstrates the value of Ang2 as a fibrosis marker, confirming
earlier findings [25,28,29]. Ang1 and Ang2 levels correlated well
but inversely with fibrosis stage and performed adequately,
particularly Ang-2, which had AUC- values above 0.70 in
discriminating all, significant, moderate, and severe fibrosis. The
involvement of angiopoietin/Tie2 signaling in vascular homeosta-
sis, immune regulation, and tissue remodeling–processes that are
significantly altered in CLD–highlights the importance of these
data. Further, elevated Ang2 expression levels have been linked to
cancer, particularly HCC; thus, the value of this factor in
monitoring CLD progression might surpass its significance as a
tool in assessing fibrosis.
Our model, which comprises all independent significant
variables–age, platelet count, INR, AST, and GGT, which have
been linked to liver fibrosis [10]–and Ang2, was accurate in
discriminating F.1, F.2, and F.3 (AUC .0.910, all) in the
training set of CHC patients (n = 107). Notably, this model
retained its outstanding precision with the validation group and
had greater accuracy and correlation with fibrosis than other
noninvasive fibrosis indices–APRI, FIB4, KING, and AAR,
GUCI, Lok, Forns, FI, FCI–in the total cohort of CHC patients
(Table 4 and Table S2).
The AUC values of AngioScore were the highest with regard to
the diagnosis of F.1 (0.886), F.2 (0.920), and F.3 (0.923),
suggesting that it is an effective test that performs accurately in
discriminating liver fibrosis stages, minimizing possible selection
bias that is attributable to prevalence. Nonetheless, when the data
were corrected and analyzed by fibrosis prevalence from a
documented extensive cohort of CHC patients (n = 33,121) [40],
the liver fibrosis model had the same or better accuracy. Further,
the excellent AUC values of our model in discriminating between
fibrosis stages (around 0.9) demonstrates that it functions as well as
LB [42].
The analysis of the criteria of our model yielded a diagnostic
cutoff 1.58 in discarding significant fibrosis with elevated sensitivity
Table 3. Cont.
F.1
AUC-ROC
(95%CI) Cutoffa Se 95%CI Sp 95%CI +LR 95%CI 2LR 95%CI +PV 95%CI 2PV 95%CI ACC
AAR 0.643
(0.568–0.713)
.0.5444 96.77 83.3–99.9 31.08 23.7–39.2 1.40 1.2–1.6 0.100 0.010–
0.700
16.1 10.2–23.6 98.6 90.2–100.0 39.0
GUCI 0.896
(0.841–0.936)
.32.9412 100.00 88.8–100.0 70.07 62.0–77.3 3.34 2.6–4.3 0 – 31.3 20.6–43.7 100.0 96.7–100.0 73.7
LOK 0.882
(0.825–0.926)
.–0.3791 83.87 66.3–94.5 85.71 79.0–90.9 5.87 3.8–9.0 0.19 0.080–
0.400
44.5 28.8–61.0 97.5 93.3–99.4 85.5
FORNSb 0.849
(0.787–0.899)
.6.5692 70.00 50.6–85.3 85.31 78.4–90.7 4.77 3.0–7.5 0.35 0.200–
0.600
39.4 23.6–57.0 95.4 90.4–98.3 83.5
FIc 0.805
(0.737–0.861)
.2.0300 75.86 56.5–89.7 79.29 71.6–85.7 3.66 2.5–5.4 0.30 0.200–
0.600
33.3 20.1–48.7 96.0 90.8–98.7 78.9
FCId 0.750
(0.677–0.813)
.0.2069 48.28 29.4–67.5 92.81 87.2–96.5 6.71 3.3–13.6 0.56 0.400–
0.800
47.8 25.3–70.9 92.9 87.5–96.5 87.5
aYouden index criterion; Se, Sensitivity; Sp, Specificity; +LR, Positive Likelihood ratio; -LR, Negative Likelihood ratio; +PV, Positive predictive value; -PV, Negative
predictive value; ACC, Accuracy. n = 178 CHC patients except for bn = 173, cn = 169 and dn = 168.
doi:10.1371/journal.pone.0066143.t003
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(.90%) and well-classified patients (67.5%) and demonstrated the
significance of 2.40 and 3.07 as optimal values of this index in
diagnosing moderate and severe fibrosis, respectively, with high
specificity (.90%) and accuracy (,90%); by applying these
criteria, 83.4% and 67.7% of patients were identified as having
F.2 and F.3, respectively. Although the optimal values for the
GUCI and FCI indices had marginally better accuracy (91.1%
and 91.7%, respectively) than our model (90.7%) in discriminating
F.3 (Table 3), they had weaker sensitivity (35.48% and 31.03%
vs. 67.64%, respectively).
Unfortunately, the high cost of Fibrotest prevented us from
comparing it with our novel liver fibrosis model; however,
AngioScore has shown better diagnostic accuracy for all signifi-
cant, moderate, and severe fibrosis than Fibrotest and Fibroscan–
the most widely used noninvasive methods of liver fibrosis staging–
in most studies [55].
Although our findings validate Ang2 as a valuable biomarker of
liver fibrosis, they are preliminary; thus, further studies in
extended cohorts of patients should be performed to verify the
significance of our model in monitoring the evolution of CHC and
its potential to predict the progression of other CLDs. In addition,
this model is less complicated and cheaper, because it can be
calculated easily from standard parameters (age, platelet count,
INR, AST, and GGT) and serum Ang2 levels during a patient’s
visit, obviating the need for complex formulas and costly
equipment. Moreover, this model significantly improves the
precision of other indices of liver fibrosis. Our index is more
accurate, less invasive, and cheaper than many existing predictive
tools for liver fibrosis staging and can help clinical decision-making
during patient follow-up.
In conclusion, angiopoietins correlate significantly with liver
fibrosis, and our new fibrosis model–comprising Ang2, age,
platelet count, INR, AST, and GGT–predicts significant, moder-
ate and severe fibrosis-cirrhosis in CHC patients with outstanding
accuracy and superior diagnostic performance compared with
other noninvasive liver fibrosis indices. Further studies should
confirm its efficacy for CHC and CLDs of distinct etiologies.
Supporting Information
Table S1 Comparisons between AngioScore AUC-ROCs
from training and validation groups of CHC patients.
(DOC)
Table S2 Correlations of different liver fibrosis indices
with liver fibrosis in the total cohort of CHC patients.
(DOC)
Table 4. Comparison of AUC values from all noninvasive liver
fibrosis indices in the total cohort of CHC patients.
F.1
INDICES AUC-ROC (95% CI) Standard Error p
AS 0.886 (0.829–0.928) 0.0273 –
APRI 0.822 (0.758–0.875) 0.0359 0.012
FIB4 0.855 (0.795–0.903) 0.0312 0.272
KING 0.855 (0.795–0.903) 0.0315 0.132
ASTALT 0.554 (0.477–0.628) 0.0533 ,0.001
GUCI 0.816 (0.751–0.870) 0.0362 0.004
LOK 0.683 (0.609–0.750) 0.0478 ,0.001
FORNSa 0.860 (0.799–0.908) 0.0322 0.245
FIb 0.675 (0.598–0.745) 0.0456 ,0.001
FCIc 0.522 (0.443–0.599) 0.0513 ,0.001
F.2
INDICES AUC-ROC (95% CI) Standard Error p
AS 0.920 (0.870–0.955) 0.0204 –
APRI 0.882 (0.825–0.925) 0.0260 0.047
FIB4 0.880 (0.823–0.924) 0.0249 0.060
KING 0.896(0.842–0.937) 0.0229 0.121
ASTALT 0.617 (0.542–0.689) 0.0435 ,0.001
GUCI 0.881 (0.825–0.925) 0.0260 0.035
LOK 0.771 (0.702–0.831) 0.0356 ,0.001
FORNSa 0.857 (0.796–0.905) 0.0277 0.003
FIb 0.764 (0.693–0.826) 0.0392 ,0.001
FCIc 0.696 (0.621–0.765) 0.0424 ,0.001
F.3
INDICES AUC-ROC (95% CI) Standard Error p
AS 0.923 (0.873–0.957) 0.0217 –
APRI 0.887 (0.831–0.930) 0.0254 0.084
FIB4 0.858 (0.798–0.906) 0.0316 0.011
KING 0.878 (0.821–0.923) 0.0269 0.027
ASTALT 0.643 (0.568–0.713) 0.0503 ,0.001
GUCI 0.896 (0.841–0.936) 0.0244 0.162
LOK 0.882 (0.825–0.926) 0.0328 0.179
FORNSa 0.849 (0.787–0.899) 0.0335 0.004
FIb 0.805 (0.737–0.861) 0.0476 0.001
FCIc 0.750 (0.677–0.813) 0.0538 ,0.001
Two sided p values by De Long test. n = 178, except for an = 173, bn = 169 and
cn = 168. AS, AngioScore.
doi:10.1371/journal.pone.0066143.t004
Figure 3. Clinically relevant criteria of a novel noninvasive liver
fibrosis index, AngioScore. Diagnostic criteria of AngioScore
obtained from the total cohort of CHC patients (n = 178). A) Corrected
optimal cutoffs for diagnosing F.1, F.2, and F.3. B) Cutoffs obtained
for sensitivities and specificities above 90%. Criteria for excluding F.1
and identifying F.2 and F.3 are shown in bold. n: number of patients
in the corresponding category; WC: well-classified patients.
doi:10.1371/journal.pone.0066143.g003
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Table S3 Comparisons among different diagnostic
criteria from analyzed liver fibrosis indices fibrosis in
the total studied cohort of CHC patients.
(DOC)
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